Cost effective interventions for the prevention of cardiovascular disease in low and middle income countries: A systematic review

BMC Public Health

Volumn 13, Issue 1, 2013, Pages

  Shroufi, Amir ^a   Chowdhury, Rajiv ^a   Anchala, Raghupathy ^a   Stevens, Sarah ^b   Blanco, Patricia ^a   Han, Tha ^a   Niessen, Louis ^c,d,e   Franco, Oscar H ^a,f  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Eastbrook   (United Kingdom)

^c Centre for Control of Chronic Diseases (CCCD) Icddrb   (Bangladesh)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; ECONOMICS; HEALTH CARE QUALITY; HEALTH PROMOTION; HUMAN; REVIEW;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HEALTH PROMOTION; HUMANS; PROGRAM EVALUATION;

MLCS; MLOWN;

EID: 84875352060     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-13-285     Document Type: Article

References (54)

1. Selected major risk factors and global and regional burden of disease. Ezzati M, Lopez AD, Rodgers A, Hoorn SV, Murray CJL, Comparative Risk Assessment Collaborating Group, Lancet 2002 360 9343 1347 1360 10.1016/S0140-6736(02) 11403-6 12423980
2. A strategy to reduce cardiovascular disease by more than 80%. Wald NJ, Law MR, BMJ 2003 326 7404 1419 10.1136/bmj.326.7404.1419 12829553
3. Estimates of global and regional potential health gains from reducing multiple major risk factors. Ezzati M, Hoorn SV, Rodgers A, Lopez AD, Mathers CD, Comparative Risk Assessment Collaborating Group, Lancet 2003 362 9380 271 280 10.1016/S0140-6736(03)13968-2 12892956
4. A community programme to reduce salt intake and blood pressure in Ghana [ISRCTN88789643]. Cappuccio FP, Kerry SM, Micah FB, Rhule JP, Eastwood JB, BMC Public Health 2006 6 13 10.1186/1471-2458-6-13 16433927
5. Comparative cost-effectiveness of policy instruments for reducing the global burden of alcohol, tobacco and illicit drug use. Chisholm D, Doran C, Shibuya K, Rehm J, Drug Alcohol Rev 2006 25 6 553 565 10.1080/09595230600944487 17132573
6. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, Appel LJ, Whelton PK, BMJ 2007 334 7599 885 888 10.1136/bmj.39147.604896.55 17449506
7. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Khatib O, Leowski J, Ewen M, Bull World Health Organ 2007 85 4 279 288 10.2471/BLT.06.033647 17546309
8. Dietary approaches to stop hypertension: a summary of study results. DASH Collaborative Research Group. Harsha DW, Lin PH, Obarzanek E, Karanja NM, Caballero B, J Am Diet Assoc 1999 99 8 Suppl 35 S39 10450292
9. The burden and costs of chronic diseases in low-income and middle-income countries. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K, Lancet 2007 370 9603 1929 1938 10.1016/S0140-6736(07)61696-1 18063029
10. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Methods for the Economic Evaluation of Health Care Programmes Oxford: Oxford University Press 3 2005
11. National Institute for Health and Clinical Excellence, Methods for development of NICE public health guidance March 2006
12. World Health Organisation, Choosing Interventions that are Cost Effective (WHO-CHOICE) [Internet] Available from: http://www.who.int/choice/ interventions/rf-tobacco/en/index.html. [Last accessed January 2011]
13. PRISMA statement. Moher D, Altman DG, Liberati A, Tetzlaff J, Epidemiology 2011 22 1 128 author reply 128 21150360
14. Community-based non-communicable disease interventions: lessons from developed countries for developing ones. Nissinen A, Berrios X, Puska P, Bull World Health Organ 2001 79 10 963 970 11693979
15. Akkazieva B, Chisholm D, Akunov N, Jacab M, The health effects and costs of the interventions to control cardiovascular disease in Kyrgyzstan 2009 [Internet] Available from: http://hpac.kg/images/pdf/prp60cvd-eng.pdf. [Last accessed Dec 2010]
16. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration, BMJ 2002 324 7329 71 86 10.1136/bmj.324.7329.71 11786451
17. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost effectiveness and resource allocation: C/E. Rubinstein A, García Martí S, Souto A, Daniel F, Augustovski F, 2009 7 10
18. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Gaziano TA, Opie LH, Weinstein MC, Lancet 2006 368 9536 679 686 10.1016/S0140-6736(06)69252-0 16920473
19. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Qizilbash N, Taylor JO, Hennekens CH, Lancet 1990 335 8693 827 838 10.1016/0140-6736(90)90944-Z 1969567
20. Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country-the case of Tanzania. Cost effectiveness and resource allocation: C/E. Robberstad B, Hemed Y, Norheim OF, 2007 5 3
21. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Heart Protection Study Collaborative Group, Lancet 2003 361 9374 2005 2016 12814710
22. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood Pressure Lowering Treatment Trialists' Collaboration, Lancet 2000 356 9246 1955 1964 11130523
23. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Murray CJL, Lauer JA, Hutubessy, Niessen L, Tomijima N, Lawes CM, Evans DB, Lancet 2003 361 9359 717 725 10.1016/S0140-6736(03)12655-4 12620735
24. Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam. Ha DA, Chisholm D, Health Policy Plan 2010 26 210 222 20843878
25. International economic analysis of primary prevention of cardiovascular disease with Pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. Caro J, Klittich W, McGuire A, Ford I, Pettit J, Norrie J, Shepherd J, Eur Heart J 1999 20 4 263 268 10.1053/euhj.1999.1193 10099920
26. Prevention of coronary heart disease with Pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, Packard CJ, N Engl J Med 1995 333 20 1301 1307 10.1056/NEJM199511163332001 7566020
27. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Law MR, Wald NJ, Rudnicka AR, BMJ 2003 326 7404 1423 10.1136/bmj.326.7404.1423 12829554
28. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Law MR, Wald NJ, Morris JK, Jordan RE, BMJ 2003 326 7404 1427 10.1136/bmj.326.7404.1427 12829555
29. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985 291 6488 97 104
30. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Gaziano TA, Steyn K, Cohen DJ, Weinstein M, Opie L, Circulation 2005 112 23 3569 3576 10.1161/CIRCULATIONAHA. 105.535922 16330698
31. Reductions in smoking prevalence and cigarette consumption associated with mass-media campaigns. Friend K, Levy DT, Health Educ Res 2002 17 1 85 98 10.1093/her/17.1.85 11888047
32. Jamison DT, Disease control priorities in developing countries [electronic resource] Washington: IBRD/The World Bank and Oxford University Press 2006
33. Tobacco control in developing countries Oxford, UK: Oxford Univ Pr, Jha P, Chaloupka FJ, 2000 237 272
34. The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles. Gilbert AR, Pinget C, Bovet P, Cornuz J, Shamlaye C, Paccaud F, Tob Control 2004 13 2 190 195 10.1136/tc.2003.004630 15175539
35. Nicotine replacement therapy for smoking cessation. Stead LF, Perera R, Bullen C, Mant D, Lancaster T, Cochrane Database Syst Rev 2004 3 D000146
36. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand. Thavorn K, Chaiyakunapruk N, Tob Control 2008 17 3 177 182 10.1136/tc.2007.022368 18285385
37. A randomized controlled trial of a smoking cessation intervention based in community pharmacies. Maguire TA, McElnay JC, Drummond A, Addiction 2001 96 2 325 331 10.1046/j.1360-0443.2001.96232516.x 11182878
38. Antidepressants for smoking cessation. Hughes JR, Stead LF, Lancaster T, Cochrane Database Syst Rev 2007 1 D000031
39. Cost-effectiveness of population wide educational approaches to reduce serum cholesterol levels. Tosteson AN, Weinstein MC, Hunink MG, Mittleman MA, Goldman PA, Goldman L, Circulation 1997 95 1 24 30 10.1161/01.CIR.95.1.24 8994412
40. Effect of longer-term modest salt reduction on blood pressure. He FJ, MacGregor GA, Cochrane Database Syst Rev 2004 3 D004937
41. By how much does dietary salt reduction lower blood pressure? III-Analysis of data from trials of salt reduction. Law MR, Frost CD, Wald NJ, BMJ 1991 302 6780 819 824 10.1136/bmj.302.6780.819 1827353
42. Understanding the variability in the effectiveness of community heart health programs: a meta-analysis. Sellers DE, Crawford SL, Bullock K, McKinlay JB, Soc Sci Med 1997 44 9 1325 1339 10.1016/S0277-9536(96)00263-8 9141165
43. How far should salt intake be reduced? He FJ, MacGregor GA, Hypertension 2003 42 6 1093 1099 10.1161/01.HYP.0000102864.05174.E8 14610100
44. By how much does dietary salt reduction lower blood pressure? II-Analysis of observational data within populations. Frost CD, Law MR, Wald NJ, BMJ 1991 302 6780 815 818 10.1136/bmj.302.6780.815 2025704
45. Cost-effectiveness analysis of Beijing Fangshan cardiovascular prevention program in 1992-1997. Huang G, Gu D, Wu X, Duan X, Xu X, Wu J, Xie B, Zhonghua Yu Fang Yi Xue Za Zhi 2000 34 2 78 80 11860903
46. Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: an analysis of the EUROPA study including 1251 Polish patients. Redekop WK, Orlewska E, Maciejewski P, Rutten FFH, Niessen L, Pharmacoeconomics 2008 26 10 861 877 10.2165/00019053-200826100-00006 18793033
47. The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention. Scuffham PA, Kósa J, Cardiovasc Drugs Ther 2006 20 4 309 317 10.1007/s10557-006-8877-3 16779529
48. Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario. Araujo D, Bahia L, Souza C, Int J Atheroscler 2007 2 3 189 194
49. Scaling up interventions for chronic disease prevention: the evidence. Gaziano TA, Galea G, Reddy KS, Lancet 2007 370 9603 1939 1946 10.1016/S0140-6736(07)61697-3 18063028
50. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Michos ED, Nasir K, Braunstein JB, Rumberger JA, Budoff MJ, Post WS, Blumenthal RS, Atherosclerosis 2006 184 1 201 206 10.1016/j.atherosclerosis.2005.04.004 15907856
51. Relation of Framingham risk score to subclinical atherosclerosis evaluated across three arterial sites. Karim R, Hodis HN, Detrano R, Liu CR, Mack WJ, Am J Cardiol 2008 102 7 825 830 10.1016/j.amjcard.2008.05.039 18805105
52. Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we? Shah PK, J Am Coll Cardiol 2010 56 2 98 105 10.1016/j.jacc.2009.09.081 20620724
53. Limitations of the Framingham risk score are now much clearer. Schlendorf KH, Nasir K, Blumenthal RS, Prev Med 2009 48 2 115 116 10.1016/j.ypmed.2008.12. 002 19124038
54. Low utilization of health care services following screening for hypertension in Dar es Salaam (Tanzania): a prospective population-based study. Bovet P, Gervasoni JP, Mkamba M, Balampama M, Lengeler C, Paccaud F, BMC Public Health 2008 8 407 10.1186/1471-2458-8-407 19087300